OttoMetzgerMD

PubMed

• 14 citations
  Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
  Adrienne G Waks, Esther R Ogayo, Laia Paré, Mercedes Marín-Aguilera, Fara Brasó-Maristany
  JAMA Oncology. 2023-06-01
• 16 citations
  Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer.
  Olga Kantor, Stephanie Wong, Anna Weiss, Otto Metzger, Elizabeth A Mittendorf
  NPJ Breast Cancer. 2020-01-01
• 28 citations
  Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach
  Anna Weiss, Stephanie M. Wong, Mehra Golshan, Rachel A. Freedman, Otto Metzger
  Annals of Surgical Oncology. 2019-09-27

Journal Articles

• Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first line trastuzu...  
  Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU, Clin Breast Cancer, 8/1/2013
• The magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: Results from the HERA trial  
  Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R..., J Clin Oncol, 6/1/2013
• Analysis of Regional Timelines to Set up a Global Phase III Clinical Trial in Breast Cancer: The ALTTO Experience  
  Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu ..., Oncologist, 1/1/2013
• Clinical development of insulin-like growth factor receptor-1 (IFG-1R) inhibitors: At the crossroad?  
  Gombos A, Metzger-Filho O, Dal Lago L, Awada-Hussein A, Invest New Drugs, 12/1/2012
• Risk-Benefit assessment of bevacizumab in the treatment of breast cancer  
  Dienstmann R, Ades F, Saini KS, Metzger-Filho O, Drug Saf, 1/1/2012
• Beyound trastuzumab: New treatment options for HER2-positive breast cancer  
  Saini KS, Azim H, Metzger-Filho O, Loi S, Sotiriou C, de Azambuja E, Piccart M, The Breast, 1/1/2011
• DNA methylation profiling reveals a predominant immune component in breast cancers  
  Dedeurwaerder S, Desmedt C, Calonne E, Singhal S.K, Haibe-Kains B, Luciani J, Putmans P, Lallemand F, Larsimont D, Toussaint J, Haussy S, Rothe F, Rouas G, Metzger O, ..., EMBO Mol Med, 1/1/2011
• First-line systemic treatment of ovarian cancer – A critical review of available evidence and expectations for future directions  
  Metzger-Filho O, Moulin C, D'Hondt V, Curr Opin Oncol, 9/1/2010
• Prevention and management of targeted therapies toxicities in breast cancer  
  Metzger-Filho O, Saini H, Azim, H, Awada, A, Crit Rev Oncol Hematol, 9/1/2010
• Use of gene expression profiling to identify breast cancer patients at an increased risk of metastasis  
  Revista Brasileira de Cancerologia, Hot Topics in Oncology, 1/1/2010
• Changing Clinical Pictures of Challenging Tumors: Tales Coming to Reality?  
  Metzger-Filho O, Moulin C, Awada A, Future Oncol, 8/1/2009
• Larotaxel: broadening the road with the new taxanes  
  Metzger-Filho O, Moulin C, Awada A, Expert Opin Investig Drugs, 8/1/2009
• High-Grade Non-Hodgkin Lymphoma – Literature Review  
  Araujo LH, Metzger-Filho O, Scheliga A, et al., Revista Brasileira de Cancerologia, 1/1/2008
• Thyrotoxic hypocalemic periodic paralysis: Report of three cases  
  Mirachi GB, Metzger-Filho O, Codo CB, Moura BS, Ferraz DP, Codo JAD, Arq Bras Endocrinol Metabol, 12/1/2004
• Rening-angiotensin system and congestive heart failure – A review article  
  Silva RF, Brant LCC, Metzger-Filho O, Coelho RR, Batista R, Santos RAS, Revista de Cardiologia Orgao de Divulgacao Cientifica da SBC/MG Sociedade Mineira de Cardiologia, 1/1/2003
• Acute retroviral syndrome  
  Metzger-Filho O, Pedroso ERP, Rev Med Minas Gerais, 1/1/2002
• Metastatic melanoma and vitiligo  
  Murad M, Metzger-Filho O, Murad AM, Revista da Sociedade Brasileira de Cancerologia, 1/1/2002
• Congestive heart failure with preserved ejection fraction  
  Fialho EL, Vitor EHC, Metzger-Filho O, Moreira PCL, Bastianetto P, Moeira MCV, Revista de Cardiologia Orgao de Divulgacao Cientifica da SBC/MG Sociedade Mineira de Cardiologia, 1/1/2002
• Join now to see all

Lectures

• HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. 
  2019 ASCO Annual Meeting - 6/1/2019
• Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. 
  2019 ASCO Annual Meeting - 6/1/2019